Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy.

Core Evid · 2016 · PMC4936814 · PMID 27445644

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

almost significantP =0.06so close (0.05 < p ≤ 0.1)

In this study, there was an almost significant difference between the mean reduction of FVC in the year prior to and after pirfenidone introduction (6.3% vs 1.3%; P =0.06), whereas no differences have been observed with regard to DL CO and 6MWT.

also in 1,858 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.